“Adjuvants are essential components of modern vaccines. However, getting access to GMP grade adjuvants has been an ongoing challenge for the vaccine community. We are excited that this co-development will enable for the first time the vaccine community to openly access an oil-in-water adjuvant suitable for use with human prophylactic vaccines”
Vaccine Adjuvants for Human HealthFor safe and effective vaccines
For more than 30 years, SEPPIC has developed, manufactured and supplied open access adjuvants solutions in human health. SEPPIC has a strong expertise in therapeutic vaccines and in particular in oncology. Now, Seppic also focuses on the prevention of infectious diseases with prophylactic vaccines adjuvant.
An adjuvant is used in the composition of a vaccine to increase, prolong, and/or modulate an immune response against the targeted antigen.
Our adjuvants for therapeutic vaccines
Therapeutic vaccines, or active immunotherapies (acting on the immune system), are administered to patients to assist the body in defending against an existing disease by activating and modulating the body's own immune response. They are particularly used in the treatment of cancers, autoimmune diseases, and certain chronic infectious diseases.
Seppic offers injectable adjuvants for formulating more effective therapeutic vaccines. These ready-to-use oily adjuvants are used in the manufacturing of stable emulsions by mixing with the aqueous phase containing the antigens.
The adjuvants are currently used in numerous clinical trials worldwide. Our lead adjuvant, MONTANIDE™ ISA 51 VG, is part of the first therapeutic vaccines against non-small cell lung cancer approved by the health authorities of seven countries.
Our therapeutic vaccines are manufactured following the Good Manufacturing Practices (GMP). Sterile grades are produced under aseptic conditions in a pharmaceutical establishment.
Our adjuvants for prophylactic vaccines
Prophylactic vaccines are administered to healthy populations as part of infectious diseases prevention. In some cases, these vaccines require the use of adjuvants to enhance the immune response and obtain appropriate protection.
While adjuvants are key components for a more effective prophylactic vaccine, several adjuvant technologies, which have proven to be safe and effective, are not commercially available. Ensuring access to these critical technologies is an imperative for the global health of populations.
With its extensive expertise, Seppic is addressing this issue by co-developing SEPIVAC SWE™, a GMP emulsion-based adjuvant available in open access for prophylactic vaccines. SEPIVAC SWE™ is the result of several years of co-development with the Vaccine Formulation Institute (VFI) which aims to provide a safe and effective adjuvant in open access, available to the whole vaccine community throughout the world. It is based on a technology recognised for its efficacy in seasonal and pandemic influenza vaccines and with a wide range of other antigens. Indeed, SEPIVAC SWE™ was successfully tested in preclinical studies with various COVID-19 antigens.
Making our adjuvant technologies available to and for all reflects our commitment to ensuring that each and every person enjoys a healthy life.